HUTCHMED (China) Limited ADR (HCM) Unusual Options Activity Today

Checking HCM unusual options activity helps you spot when traders are making outsized bets on HUTCHMED (China) Limited ADR before the broader market catches on. HUTCHMED (China) Limited ADR's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor HCM unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching HCM unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking HCM unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and HCM unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta).

In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Catalysts rarely arrive without a footprint, and HCM unusual options activity is often where that footprint shows up first. Our scanner tracks HUTCHMED (China) Limited ADR's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at HCM unusual options volume on the call side or chasing put sweeps, HUTCHMED (China) Limited ADR's unusual options flow today is one click away, so put it on your radar before the headlines hit.